Thiotepa added to standard chemo before a stem cell transplant for older adults with high-risk AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding a drug called thiotepa to the usual chemotherapy (busulfan and fludarabine) before a half-matched stem cell transplant can safely and effectively treat older adults (55–70) with high-risk AML.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 70 years old.
- You have a high-risk form of acute myeloid leukemia (AML), which may include leukemia that came back after treatment or is hard to treat.
- You are planning to receive a stem cell transplant from a half-matched family donor (haploidentical transplant).
- Your major organs (heart, liver, kidneys, lungs) work well enough for the transplant.
- You are still able to do most daily activities (like walking and getting dressed) with little or no help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new chemotherapy preparation (using thiotepa) before a stem cell transplant from a matched donor to treat blood cancers like leukemia and myelodysplastic syndrome. The goal is to improve survival while reducing severe side effects.
This trial tests a special preparation (conditioning) regimen for patients 55 or older with acute myeloid leukemia (AML) who are in first remission and receiving a half-matched (haploidentical) stem cell transplant. It aims to make the transplant safer and more effective for this age group.
This trial tests a chemotherapy regimen (thiotepa-containing preparation) combined with a stem cell transplant from a donor to treat chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if this approach helps patients with intermediate-to-high risk disease achieve remission.
This trial tests a chemotherapy conditioning regimen called TBF before a haploidentical stem cell transplant (using cells from a partially matched family donor) in adults ages 55–75 with acute myeloid leukemia that has responded well to initial treatment. The goal is to see if this approach helps older patients tolerate transplant and achieve long-term remission.
This trial tests a gentler chemotherapy regimen before a stem cell transplant from a partially matched family donor for patients with acute myeloid leukemia (AML) who are older or have health conditions that make standard transplants risky. The goal is to help patients achieve long-term remission with fewer serious side effects.
This trial tests a new drug combination to help people with relapsed or refractory acute myeloid leukemia (AML) get ready for a stem cell transplant. The goal is to make the transplant more effective and improve outcomes.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.